Biosimilar rituximab, marketed in Argentina as Novex, is subject to an active pharmacovigilance program that, according to Argentine law, must periodically report its status and results to regulatory authorities. In a recent study, researchers examined pharmacovigilance reports to compare the safety profile of biosimilar rituximab with that of its reference.
Biosimilar rituximab, marketed by Laboratorio Elea in Argentina as Novex, is subject to an active pharmacovigilance program that, according to Argentine law, must periodically report its status and results to regulatory authorities. In a study published in the June 7, 2017 issue of Hematological Oncology, researchers examined these pharmacovigilance reports in an effort to compare the safety profile of biosimilar rituximab with that of its reference.
A prospective treatment registry has been in place since the launch of the rituximab biosimilar. Prescribers are directed to report the age, gender, treatment start date, related pathology, dosing, and dose frequency for each patient receiving the biosimilar treatment. After a pre-determined period of time, physicians report treatment outcomes and occurrences of adverse events. For each adverse event, treating physicians file Individual Case Safety Reports (ICSRs).
Between November 26, 2014, to February 28, 2017, physicians registered a total of 584 patients who had been prescribed the biosimilar rituximab for non-Hodgkin’s Lymphoma. Among this group, 378 patients had at least 1 follow-up and were included in the analysis.
The median treatment duration was 214 days (interquartile range: 155 to 306). A mean of 5.7 cycles of rituximab were administered (range: 1 to 12). The total number of ICSRs filed was 15, and the occurrence rate was 1 ICSR filed per 100 cycles administered. Among adverse events reported on ICSRs, 10 were reported as being serious.
The adverse events reported are as follows (1 ICSR reported 2 events):
The researchers concluded that the biosimilar rituximab product demonstrated a safety profile similar to that of the reference product, and that the 2 products had comparable tolerability. The researchers further noted that the pharmacovigilance program showed great value in allowing for continuous monitoring of biosimilar product safety.
Disease Activity, Safety Remain Following Switch From Infliximab Biosimilar to Remicade in IBD
February 15th 2025Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.
Biosimilars in Action: Market Shifts, Legal Insights, and FDA Approvals
February 9th 2025In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA approvals, patent disputes, and biosimilar market trends shaping the health care landscape.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.